Good report, I liked this......
The 2nd dose cohort of the Phase 1 trial was completed in December, with all patients advancing past the
28 day follow up period with no dose-limiting toxicities.
The study has advanced to the 3rd dose cohort, which will administer CLTX CAR T cells to patients through the dual routes of administration at an
increased total dose of 220 X 106 CLTX CAR T cells.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.747M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $27.16K | 8.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 69 | 66853948 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 94845096 | 28 |
View Market Depth
| Last trade - 16.10pm 29/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |